Upmc Hillman Cancer Center

Clinical research site in Pittsburgh, Pennsylvania · 1000 BOWER HILL RD, PITTSBURGH, PA 15243-1873 · (412) 942-7075 · Website

Part of UPMC Hillman Cancer Center

As of July 2026, 88 paid clinical trials are recruiting at Upmc Hillman Cancer Center in Pittsburgh, Pennsylvania. Active studies at this site cover conditions such as Melanoma, Hepatocellular Carcinoma and Glioma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Upmc Hillman Cancer Center (88)

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

104 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

for COVID-19 Infection

65 locations incl. Canoga Park

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07013474·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

43 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting·Listed Apr 2018

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

37 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

for Glioblastoma

32 locations incl. Phoenix

Sponsor: NovoCure GmbH

Sex: All·Age: 18+

Code: NCT06556563·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Neoadjuvant Darovasertib in Primary Uveal Melanoma

for Uveal Melanoma

35 locations incl. Scottsdale

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07015190·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

for Metastatic Uveal Melanoma

29 locations incl. Scottsdale

Sponsor: Replimune, Inc.

Sex: All·Age: All ages

Code: NCT06581406·Phase 2, Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

for Advanced Melanoma

33 locations incl. Tucson

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT06112314·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

for Gastroesophageal-junction Cancer

29 locations incl. Anaheim

Sponsor: Shanghai Henlius Biotech

Sex: All·Age: 18+

Code: NCT06532006·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

for Advanced Melanoma

25 locations incl. Phoenix

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT05549297·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

for Chronic Graft-Versus-Host Disease (cGVHD)

26 locations incl. Duarte

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT06619561·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

30 locations incl. Birmingham

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting·Listed Aug 2022

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

21 locations incl. Springdale

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

for Chronic Lymphocytic Leukemia (CLL)

20 locations incl. Duarte

Sponsor: Nurix Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07221500·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

20 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for Relapsed/Refractory Primary Central Nervous System Lymphoma

20 locations incl. Phoenix

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07104032·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

for HR+ Breast Cancer

18 locations incl. Duarte

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07029399·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for Solid Tumors With HRAS Alterations

22 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06026410·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

for Ovarian Cancer

17 locations incl. Duarte

Sponsor: Xencor, Inc.

Sex: All·Age: 15+

Code: NCT06276491·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

for Recurrent Melanoma (Skin)

12 locations incl. Orange

Sponsor: Perspective Therapeutics

Sex: All·Age: 18 - 90

Code: NCT05655312·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

9 locations incl. Orange

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

for Unresectable Melanoma

10 locations incl. Los Angeles

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05361174·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

for Sickle Cell Disease Vaso-occlusive Crisis

16 locations incl. Oakland

Sponsor: CSL Behring

Sex: All·Age: 12+

Code: NCT06699849·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

for Advanced Or Metastatic Merkel Cell Carcinoma

18 locations incl. Los Angeles

Sponsor: TuHURA Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT06947928·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for Oncology

13 locations incl. San Francisco

Sponsor: Nested Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06326411·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

for Hepatocellular Carcinoma

12 locations incl. Beverly Hills

Sponsor: Replimune, Inc.

Sex: All·Age: 18+

Code: NCT05733598·Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

for Head and Neck Squamous Cell Carcinoma

15 locations incl. La Jolla

Sponsor: Bicara Therapeutics

Sex: All·Age: 18+

Code: NCT04429542·Phase 1·Recruiting·Listed Jun 2020

Apply to this trial

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

for Cancer

15 locations incl. Los Angeles

Sponsor: Krystal Biotech, Inc.

Sex: All·Age: 18+

Code: NCT05970497·Phase 1, Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for Solid Tumor

20 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04939610·Phase 1, Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

for Oesophageal Squamous Cell Carcinoma

1 location in Pittsburgh

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07405151·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

for EGFR Mutation Positive Non-small Cell Lung Cancer

6 locations incl. Calverton

Sponsor: Nuvectis Pharma, Inc.

Sex: All·Age: 18+

Code: NCT07315113·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

for CLL / SLL

4 locations incl. Bethesda

Sponsor: Newave Pharmaceutical Inc

Sex: All·Age: 18+

Code: NCT07342478·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

for Chronic Lymphocytic Leukemia

6 locations incl. Miami Beach

Sponsor: Curis, Inc.

Sex: All·Age: 18+

Code: NCT07271667·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

for Colorectal Cancer

6 locations incl. Aurora

Sponsor: Kahr Bio Australia Pty Ltd

Sex: All·Age: 18+

Code: NCT07235293·Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

for Solid Tumours

9 locations incl. Irvine

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07160725·Phase 1, Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

for Castration-Resistant Prostatic Cancer

9 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06863272·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Showing the 40 most relevant of 88 recruiting trials at this site. Browse all with filters →

More research sites in Pittsburgh

University of Pittsburgh (157 trials)
University of Pittsburgh Medical Center (131 trials)
University of Pittsburgh Cancer Institute (UPCI) (86 trials)
Allegheny General Hospital (64 trials)
Children's Hospital of Pittsburgh of UPMC (61 trials)
UPMC Children's Hospital of Pittsburgh (51 trials)
UPMC-Passavant Hospital (35 trials)
Allegheny Health Network (31 trials)
UPMC-Saint Clair Hospital Cancer Center (28 trials)
UPMC-Saint Margaret (25 trials)

Explore more

Paid clinical trials in Pittsburgh, PA · Pennsylvania clinical trials